Minocycline for patients with ALS

The Lancet Neurology

Volumn 7, Issue 2, 2008, Pages 118-119

  Carrì, Maria Teresa ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; MINOCYCLINE; NIMODIPINE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; DRUG EFFICACY; HUMAN; INFLAMMATION; LETTER; MOTONEURON; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RATING SCALE; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; MICE; MICE, KNOCKOUT; MINOCYCLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUPEROXIDE DISMUTASE; TREATMENT FAILURE;

EID: 38149037132     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70005-X     Document Type: Letter

References (5)

1. Gordon P., Moore D., Miller R., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6 (2007) 1045-1053
2. Swash M. Learning from failed trials in ALS. Lancet Neurol 6 (2007) 1034-1035
3. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26 (2007) 1-13
4. Boillée S., Yamanaka K., Lobsiger C., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312 (2006) 1389-1392
5. Kriz J., Gowing G., and Julien J. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol 53 (2003) 429-436